期刊
VACCINE
卷 28, 期 50, 页码 7825-7828出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.09.058
关键词
Pandemic influenza A/H1N1 influenza vaccine; Pandemic A/H1N1 influenza virus; MF59; Adjuvants; Vaccination; Children
资金
- Italian Ministry of Health
In order to evaluate the immunogenicity, safety, and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with beta-thalassemia major, 31 subjects (19 males; mean age 17.8 +/- 8.7 years) with beta-thalassemia major and 28 age- and gender-matched healthy controls were enrolled. Four weeks after vaccination, seroconversion rates were about 80% and seroprotection rates 100% in both groups. Three months after vaccination, most of the subjects remained seroconverted and the seroprotection rates were 93.5% among the patients and 100% among the controls. Safety and tolerability were also very good, with no differences between the groups. (C) 2010 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据